Closely-held Soricimed Biopharma and collaborators plan to present four posters at the American Association of Cancer Research (AACR) annual meeting in New Orleans on April 16-20.
The presentations are based on preclinical and clinical research conducted on the company’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel.
In February, the company announced positive top-line results from a Phase 1 trial with SOR-C13 in patients with advanced solid tumors, including lung, colon, breast and prostate cancers. Preliminary data demonstrated safety and tolerability in patients, as well as potential activity, with 54% of patients achieving stable disease.
The company’s presentations at AACR will include data demonstrating the anti-tumor targeting potential for the SOR-C series peptides, specifically targeting the TRPV6 calcium channel, a novel target in oncology, which is highly elevated in solid tumors. Phase 1 clinical trial results from SOR-C13 also showed the potential of targeting TRPV6 in advanced adenocarcinomas of the pancreas.
Soricimed’s collaborators will be presenting preclinical data on SOR-C13 in an additional poster, suggesting a novel therapeutic approach for multiple myeloma, involving TRPV6 inhibition to target both myeloma cells and osteoclasts.